

C 018

Silva Pharmaceuticals Limited
Statement of Financial Position (Unaudited)
As at 31 December 2024



Particulars	Notes	Amount in Lakh	
		31 Dec 2024	30 Sep 24
ASSETS			
Non-Current Assets		1,15,17,948	1,12,112,708
Property, Plant & Equipment	3.09	1,01,24,742	1,00,104,881
Intangible Assets	4.09	1,19,206	1,29,037
Right of use asset (ROU)	5.09	2,73,000	1,01,961
Capital work-in-progress	6.09	10,21,000	11,60,829
Current Assets		1,02,75,471	1,05,215,711
Inventories	7.09	40,84,471	40,001,811
Trade and Other Receivables	8.09	34,27,000	32,90,421
Advances, Deposits and Prepayments	9.09	26,74,106	25,00,000
Bank Deposits and Cash (BDC)	10.09	10,21,121	10,00,000
Cash and Cash Equivalents	11.09	11,71,000	12,00,000
Total Assets		2,17,93,419	2,17,328,419
Equity attributable to the shareholders			1,70,048,494
Shareholders' Funds			1,70,048,494
Reserves			1,70,048,494
Retained Earnings			1,70,048,494
Current Liabilities		1,15,17,948	1,12,112,708
Trade Payables	12.09	1,00,00,000	1,00,00,000
Current Liabilities		1,15,17,948	1,12,112,708
Trade Payables	13.09	1,00,00,000	1,00,00,000
Trade and Other Payables	14.09	15,17,948	12,112,708
Provision for doubtful debts	15.09	1,00,000	1,00,000
Unclaimed Dividend Account	16.09	1,00,000	1,00,000
Short Term Loan	17.09	1,00,000	1,00,000
Provision for Contingent Liabilities	18.09	1,00,000	1,00,000
Total Liabilities		1,15,17,948	1,12,112,708
Total Equity & Liabilities		2,17,93,419	2,17,328,419
Net Asset Value (NAV) per share	20.09	16.87	16.87
Number of Shares used to compute NAV		1,00,00,000	1,00,00,000


Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Half Yearly)

For the Period from 01 July, 2024 to 31st December, 2024

The amount set off from the original price of the financial statements.

 Director
 Managing Director
 Director


 Director
 Director
 Director

 Director
 Director
 Director


Silva Pharmaceuticals Limited
Statement of Financial Position (Un-Audited)
As at 31 December, 2024

Particulars	Notes	Amount in Taka	
		31-Dec-24	30-Jun-24
ASSETS			
Non Current Assets		1,449,679,948	1,474,712,706
Property, Plant & Equipment	3.00	1,121,247,932	1,150,164,643
Intangible Assets	4.00	1,163,406	1,224,638
Right-of-use asset (ROU)	5.00	4,995,613	5,651,962
Capital work-in-Progress	6.00	322,272,997	317,671,463
Current Assets		908,735,472	939,515,718
Inventories	7.00	460,675,433	493,201,611
Trade and Other Receivables	8.00	244,373,662	256,130,421
Advances, Deposits and Prepayments	9.00	66,745,706	62,689,093
Fixed Deposits Receipts (FDR)	10.00	83,211,623	88,801,678
Cash and Cash Equivalents	11.00	53,729,048	38,692,915
Total Assets		2,358,415,420	2,414,228,424
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,186,956,012	2,255,949,495
Share Capital	12.00	1,365,000,000	1,365,000,000
Retained Earnings	13.00	821,956,012	890,949,495
Non-Current Liabilities		83,834,099	84,114,522
Deferred Tax Liabilities	14.00	80,952,926	80,678,988
Lease liabilities	15.00	2,881,173	3,435,534
Current Liabilities		87,625,309	74,164,407
Lease liabilities	15.00	1,080,440	1,182,428
Trade and Other Payables	16.00	10,585,192	7,162,713
Dividend Payable for the year 2023-2024		9,957,150	-
Unclaimed Dividend Account	17.00	174,096	176,686
Short Term Loan	18.00	47,585,298	47,709,074
Provision for Expenses	19.00	18,243,133	17,933,506
Total Liabilities		171,459,408	158,278,929
Total Equity & Liabilities:		2,358,415,420	2,414,228,424
Net Assets Value (NAV) per share	29.00	16.02	16.53
Number of Shares used to compute NAV		136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.


 Chairman


 30.01.2025
 Managing Director / CEO (CC)


 Director


 Chief Financial Officer


 Company Secretary

Place: Dhaka;
 Dated: January 30, 2025


Silva Pharmaceuticals Limited

Statements of Profit or Loss and Other Comprehensive Income (Un-Audited)


For the Half-Year ended 31 December, 2024

Particulars	Notes	Amount in Taka			
		Half-Yearly Results		Quarterly Results	
		01/07/2024 to 31/12/2024	01/07/2023 to 31/12/2023	01/10/2024 to 31/12/2024	01/10/2023 to 31/12/2023
Revenue from Net Sales	20.00	201,634,883	302,964,998	102,530,143	151,271,909
Cost of goods sold	21.00	(141,545,937)	(215,904,074)	(69,432,631)	(108,173,792)
Gross Profit		60,088,946	87,060,924	33,097,512	43,098,117
Operating expenses		(118,165,165)	(102,728,785)	(58,532,077)	(51,751,672)
Administrative Expenses	22.00	(21,172,361)	(18,602,361)	(10,712,351)	(9,631,224)
Selling & Distribution Expenses	23.00	(96,992,804)	(84,126,424)	(47,819,726)	(42,120,448)
Operating Income		(58,076,219)	(15,667,861)	(25,434,565)	(8,653,555)
Financial expenses	24.00	(1,936,337)	(1,121,760)	(1,208,458)	(869,212)
Interest and Other income	25.00	3,365,493	2,541,361	1,926,005	1,833,721
Profit before WPPF and Welfare Fund		(56,647,063)	(14,248,260)	(24,717,018)	(7,689,046)
Worker's Profit Participation and Welfare Fund (WPP&WF)	26.00	-	-	-	-
Profit before Income Tax		(56,647,063)	(14,248,260)	(24,717,018)	(7,689,046)
Income Tax Expenses:	27.00	(2,389,270)	(1,968,349)	(1,387,930)	(874,730)
Current Tax Expenses	27.01	(2,115,332)	(1,833,038)	(1,250,961)	(918,634)
Deferred Tax expenses	27.02	(273,938)	(135,311)	(136,969)	43,904
Net Profit after tax		(59,036,333)	(16,216,609)	(26,104,948)	(8,563,776)
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the period		(59,036,333)	(16,216,609)	(26,104,948)	(8,563,776)
Earnings Per Share (EPS)	28.00	(0.43)	(0.12)	(0.19)	(0.06)
Number of Shares used to compute EPS		136,500,000	136,500,000	136,500,000	136,500,000


The annexed notes from an integral part of these financial statements.



Chairman


30.01.2025


Managing Director / CEO (cc)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: January 30, 2025


Silva Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the Half-Year ended 31 December, 2024


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2024	1,365,000,000	890,949,495	2,255,949,495
Net profit after tax during the period	-	(59,036,333)	(59,036,333)
Dividend for the year 2023-2024	-	(9,957,150)	(9,957,150)
Balance as at 31 December, 2024	1,365,000,000	821,956,012	2,186,956,012

For the Half-Year ended 31 December, 2023

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2023	1,365,000,000	969,084,309	2,334,084,309
Net profit after tax during the period	-	(16,232,359)	(16,232,359)
Dividend for the year 2022-2023	-	(13,650,000)	(13,650,000)
Balance as at 31 December, 2023	1,365,000,000	939,201,950	2,304,201,950


The annexed notes from an integral part of these financial statements.


 Chairman


 30.01.2025
 Managing Director / CEO (CC)


 Director


 Chief Financial Officer


 Company Secretary


Place: Dhaka;
 Dated: January 30, 2025

Silva Pharmaceuticals Limited
Statement of Cash Flows (Un-Audited)
For the Half-Year ended 31 December, 2024


Particulars	Notes	Amount in Taka	
		01/07/2024 to 31/12/2024	01/07/2023 to 31/12/2023
Cash flows from Operating Activities			
Cash received from Customers	30.00	213,361,362	310,313,532
Cash received from non-operating income	31.00	3,395,773	4,258,175
Cash Paid to Suppliers	32.00	(68,927,899)	(171,382,012)
Cash Paid to Employees	33.00	(109,836,365)	(92,871,949)
Cash Paid for Others	34.00	(19,847,461)	(20,237,207)
Cash payment for Financial Expenses		(1,693,826)	(1,021,404)
Income Tax Paid	35.00	(1,378,745)	(6,478,410)
Net cash inflow/(outflow) from operating activities (A)*	37.00	15,072,839	22,580,725
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment	36.00	-	(2,608,445)
Cash Payments for Capital Work-in-progress		(4,601,534)	(3,366,904)
Cash received/Payments from/to FDR		5,590,055	67,225,905
Net cash used in investing activities (B)		988,521	61,250,556
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		(123,776)	(11,750,055)
Cash payment towards lease liabilities		(898,861)	(860,295)
Cash Dividend Paid		(2,590)	(140,830)
Net cash used in financing activities (C)		(1,025,227)	(12,751,180)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		15,036,133	71,080,101
Cash and Cash Equivalents at the beginning of the period		38,692,915	28,642,612
Cash and Cash Equivalents at the end of the period	11.00	53,729,048	99,722,713
Net Operating Cash Flow Per Share (NOCFPS)	37.00	0.11	0.17

*Refer to Note 38.00 for a reconciliation between net profit with cash flows from operating activities.

The annexed notes from an integral part of these financial statements.



 Chairman


 30.01.2025

 Managing Director / CEO (CC)



 Director



 Chief Financial Officer



 Company Secretary

Place: Dhaka;
 Dated: January 30, 2025